



Great Yuhan, Global Yuhan



eng.yuhan.co.kr

Yuhan Corporation

CEO
Jung Hee Lee

Location
74, Noryangjin-ro, Daebang-dong, Dongjak-gu, Seoul, Korea

- Specialty
1. Anticancer Chemical New drug
 2. Circulatory System Incrementally Modified Drugs

Tel / Fax / E-mail
T. 82-2-828-0181
F. 82-2-828-0300

Yuhan Corporation has increased the R&D investments since 2015. We licensed out KRW 2.5 trillion worth of technology in 2018, 2019 on licensing and the joint R&D for a new therapeutic candidate treating nonalcoholic steatohepatitis (NASH). As our pipelines continue to expand, today they stand at 27 breakthrough therapies and five IMDs. In pursuit of breakthrough therapies, there are 17 ongoing oncology programs, including immunotherapies and next-generation targeted drugs to fight cancer, such as Lazertinib.

Main Products

Products	Ingredients	Indications	Exporting Countries
Pregabalin SR Tablet	Pregabalin	Neuropathic pain	
Duowell Tablet	Telmisartan, Rosuvastatin	Treatment for hypertension and hyperlipidemia	Uzbekistan
Rosuampine Tablet	Amlodipine, Rosuvastatin	Treatment for hypertension and hyperlipidemia	
Rosumet SR Tablet	Metformin SR, Rosuvastatin	Antidiabetic	
Newfactan	Bovine Lung Surfactant	Treatment for respiratory distress syndrome of newborns	Vietnam, Mongolia, Bolivia
Yucla Tablet	Amoxicillin, Clavulanate Potassium	Antibiotics	
Almagate Suspension	Almagate	Antiacidic functions	
Antiplamine S Lotion	Methyl Salicylate, L-menthol	Anti-inflammatory agent	Vietnam, Malaysia
Willogel Double Action Suspension	Sodium alginate, Calcium carbonate, Sodium bicarbonate	Alleviation of heartburn and indigestion	
Nazacare Nasal Spray Solution	Mometasone Furoate	Nasal symptoms of allergic rhinitis, Nasal polyps, Acute rhinosinusitis	

R&D Pipeline

Category	Name	Indication	Discovery	Preclinical study	Phase 1	Phase 2	Phase 3
NCE	Lazertinib	NSCLC				██████████	
	YH12852	POI				██████████	
	YHC1102	NASH	██████████				
	YHC1108	NASH	██████████				
	YHC1116	Gaucher	██████████				
	YHC1104	NSCLC	██████████				
Biologics	YH14618	Degenerative Disk				██████████	
	YH25724	NASH		██████████			
	YH24931	Immuno-oncology	██████████				
	YHC2121	Immuno-oncology	██████████				
	YHC2120	Immuno-oncology	██████████				
	YHC2110	Obesity	██████████				